FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/31/2025
Back to search
Official data from USPTO
ALEVATE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ALEVATE
ST13
US500000079350535Class
41, 42, 45
Filing
79350535
Registration
7582839
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
39
Latest update
04/03/2026
Trademark type
Word
Nice classes
41, 42, 45
Filing date
05/17/2022
Registration date
12/03/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/03/2024
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
98
Owner location
GB
Examiner
PERKINS, ELLEN J
Law office
M10
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Sartorius Albumedix Limited
Albumedix Ltd
Representatives
Karen Lim Fross Zelnick Lehrman & Zissu, P.C.
Technical classification
Nice Classes
Class 41Class 42Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 41
Educationclassesseminarsworkshops in the fields of biologymedicinebiologicalsbiopharmaceuticalspharmaceuticalschemical analysis; providing of training in the fields of biologymedicinebiologicalsbiopharmaceuticalspharmaceuticalschemical analysis; teaching and training in the fields of biologymedicinebiologicalsbiopharmaceuticalspharmaceuticals and chemical analysis; teaching and training in the fields of development and use of vaccinesgrowth factorsimmune modulatorsmonoclonal antibodiescellscell therapiestissuesproteinsrecombinant proteinsnucleic acidsgene therapiesproducts derived from living culture systemsproducts derived from human bloodproducts derived from plasma; provision of medicalbiologicalbiopharmaceuticalpharmaceutical and chemical instruction courses; organization of educational conferences in the fields of medicalbiologicalbiopharmaceuticalpharmaceutical and chemical research and development; technical training in the field of medicalbiologicalbiopharmaceuticalpharmaceutical and chemical analysis; informationconsultancy and advisory services for the aforementioned services
Class 42
Research and development services in the field of new biologicalpharmaceuticalbiopharmaceuticalchemical and medical products; technological consultancyproviding consultancy and expert assistance in the field of new product development of medicines and pharmaceutical productslaboratory analysis in the field of medicines and pharmaceuticals; researchdevelopment and laboratory analysis services relating to pharmaceutical and medicinal goodsin particularalbuminchemicalspeptidesproteinsantibodiescellsnucleic acidsviruseslive viruseslive-attenuated virusesattenuated virusesvirus-like particles and viral vectors; quality management servicesquality evaluation and analysisquality assurancequality control in the field of pharmaceuticalbiopharmaceuticalchemicalmedical products; certificationquality control services in the field of biologicalpharmaceuticalbiopharmaceuticalchemicalmedical products; certificationquality assurance services in the field of biologicalpharmaceuticalbiopharmaceuticalchemicalmedical products; process monitoringquality assurance in the field of biologicalpharmaceuticalbiopharmaceuticalchemicalmedical products; quality control services for others in the field of development and testing of cells; services of a scientific chemical and biological laboratory; development and testing of chemicalpharmaceuticalbiopharmaceuticalchemicalmedical production methods; quality control services for others and authentication services in the field of biologicalpharmaceuticalbiopharmaceuticalchemicalmedical products; process monitoringproviding quality assurance services in the field of biologicalpharmaceuticalbiopharmaceuticalchemicalmedical products; scientific and medical laboratory services; informationconsultancy and advisory services for researchtestingdevelopment in the pharmaceuticalbiopharmaceuticalchemicalmedical fieldsnone of the foregoing related to financial software
Class 45
Regulatory compliance auditing; regulatory compliance consultancy in the field of biotechnologypharmaceuticalsbiopharmaceuticalsmedical testing and research; reviewing standards and practices to assure compliance with laws and regulations in the fields of biologypharmaceuticalsbiopharmaceuticalschemicalsmedicine; informationconsultancy and advisory services for the aforementioned services
Publications
History of USPTO decisions and trademark events.
39 publications found
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
04/25/2025
XXCR
GENERIC MADRID TRANSACTION CREATED
04/25/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/16/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/16/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/16/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/16/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/16/2025
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
04/11/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/03/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/03/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
12/03/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/01/2024
PUBO
PUBLISHED FOR OPPOSITION
10/01/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/11/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/28/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/24/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/24/2024
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
06/24/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
03/18/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/28/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
02/28/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
12/31/2023
GNFR
FINAL REFUSAL E-MAILED
12/31/2023
CNFR
FINAL REFUSAL WRITTEN
12/31/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/03/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/03/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/03/2023
RFNT
REFUSAL PROCESSED BY IB
05/24/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/04/2023
RFRR
REFUSAL PROCESSED BY MPU
05/04/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/02/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/16/2023
CNRT
NON-FINAL ACTION WRITTEN
03/15/2023
DOCK
ASSIGNED TO EXAMINER
03/07/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/29/2023
MAFR
APPLICATION FILING RECEIPT MAILED
09/27/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/23/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/22/2022
Continuous trademark protection
Get notified about every new filing that threatens ALEVATE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.